ArticlePloS one2019
m6A minimally impacts the structure, dynamics, and Rev ARM binding properties of HIV-1 RRE stem IIB.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Impact of NbioRxiv : the preprint server for biology · 2025Article
- RNA infrastructure profiling illuminates transcriptome structure in crowded spaces.Cell chemical biology · 2024Article
- Functional Impacts of Epitranscriptomic mViruses · 2024Review
- Structural and computational studies of HIV-1 RNA.RNA biology · 2024Review
- Direct Analysis of HIV mRNA mMethods in molecular biology (Clifton, N.J.) · 2024Article
- RNA Infrastructure Profiling Illuminates Transcriptome Structure in Crowded Spaces.bioRxiv : the preprint server for biology · 2023Article
- Epitranscriptomics in parasitic protists: Role of RNA chemical modifications in posttranscriptional gene regulation.PLoS pathogens · 2022Review
- Regulation of antiviral innate immunity by chemical modification of viral RNA.Wiley interdisciplinary reviews. RNA · 2022Review
- Isotope Labels Combined with Solution NMR Spectroscopy Make Visible the Invisible Conformations of Small-to-Large RNAs.Chemical reviews · 2022Review
- YTHDC1 regulates distinct post-integration steps of HIV-1 replication and is important for viral infectivity.Retrovirology · 2022Article
- Epitranscriptomic addition of mGenes & development · 2021Article
- From A to mViruses · 2021Review
- 2'-O-Methylation can increase the abundance and lifetime of alternative RNA conformational states.Nucleic acids research · 2020Article
- It's the Little Things (in Viral RNA).mBio · 2020Review
- Acetylation of Cytidine Residues Boosts HIV-1 Gene Expression by Increasing Viral RNA Stability.Cell host & microbe · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
N6-methyladenosine (m6A) is a ubiquitous RNA post-transcriptional modification found in coding as well as non-coding RNAs. m6A has also been found in viral RNAs where it is proposed to modulate host-pathogen interactions. Two m6A sites have been reported in the HIV-1 Rev response element (RRE) stem IIB, one of which was shown to enhance binding to the viral protein Rev and viral RNA export. However, because these m6A sites have not been observed in other studies mapping m6A in HIV-1 RNA, their significance remains to be firmly established. Here, using optical melting experiments, NMR spectroscopy, and in vitro binding assays, we show that m6A minimally impacts the stability, structure, and dynamics of RRE stem IIB as well as its binding affinity to the Rev arginine-rich-motif (ARM) in vitro. Our results indicate that if present in stem IIB, m6A is unlikely to substantially alter the conformational properties of the RNA. Our results add to a growing view that the impact of m6A on RNA depends on sequence context and Mg2+.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.